UTAA09 injection for treating relapsed or refractory B-cell cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of UTAA09, a recombinant allogeneic healthy γδT cell infusion, in patients with CD19-positive relapsed or refractory B-cell hematolymphatic malignancies. The study is a single-arm, open-label design where all participants will receive the UTAA09 cell infusion along with Fludarabine and Cyclophosphamide. The primary objective is to assess the preliminary safety and efficacy of the treatment, while secondary objectives include monitoring the distribution and survival of the infused cells and the ratio of CD19-positive cells in the blood post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged between 3\~70 (including cut-off values), regardless of gender and race;
2. Expected survival time\>12 weeks;
3. ECOG score 0-2;
4. CD19-positive relapsed/refractory B-cell hematolymphatic malignancies;
5. Liver and kidney function, cardiopulmonary function meet the following requirements:

   1. Creatinine ≤ 1.5 ULN;
   2. Left ventricular ejection fraction ≥ 45%;
   3. blood oxygen saturation\>91%;
   4. Total bilirubin ≤ 1.5 × ULN； ALT and AST ≤ 2.5 × ULN;
6. Be able to understand the trial and have signed the informed consent.

Exclusion Criteria:

1. Those with graft-versus-host disease (GVHD) or requiring long-term systemic immunosuppressants;
2. Malignant tumors other than CD19-positive hematologic malignancies within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer, local prostate cancer after radical resection, and breast ductal carcinoma in situ after radical resection;
3. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer outside the normal reference range; Those who are positive for hepatitis C virus (HCV) antibodies and positive for hepatitis C virus (HCV) RNA in peripheral blood; Human immunodeficiency virus (HIV) antibody positive person; Positive for cytomegalovirus (CMV) DNA testing; those who test positive for syphilis;
4. Serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥ III), and serious arrhythmia;
5. Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
6. Within 7 days before screening, there is active infection or uncontrollable infection requiring systemic treatment (except for mild genitourinary system infection and upper respiratory tract infection);
7. Pregnant or lactating women, female subjects who planned to conceive within 1 year of cell infusion or male subjects whose partner planned pregnancy within 1 year of their cell infusion;
8. Screening participants (except for inhalation or local use) who were receiving systemic steroid treatment within 7 days before screening or who were judged by the investigator to require long-term systemic steroid therapy during treatment;
9. Participated in other clinical studies within 3 month before screening;
10. There was evidence of central nervous system involvement at participant screening;
11. Conditions that the investigators considered unsuitable for enrollment.

Where it's running

• The First Affiliated Hospital of USTC (AnHui Provincial Hospital)
  Hefei, Anhui, China Recruiting

Study contacts

• Principal investigator: Xingbing Wang, MD — The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
• Study coordinator: Xingbing Wang, MD
• Email: wangxingbing@ustc.edu.cn
• Phone: 13856007984

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UTAA07 CAR-γδT cell infusion for relapsed or refractory CD7-positive blood and lymphoid cancers

  This study will try UTAA07 CAR-γδT cell infusions in adults with relapsed or refractory CD7-positive hematologic and lymphoid cancers to see if they are safe and help control the disease.

  Recruiting Early Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Suzhou, Jiangsu · NCT07338604

• LV009 infusion for relapsed/refractory CD19-positive blood cancers

  This early-phase study will test whether LV009 infusion is safe and how it behaves in adults with relapsed or refractory CD19-positive blood cancers such as NHL or ALL.

  Recruiting Early Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Hefei, Anhui · NCT07312630

• LV009 injection for relapsed or refractory CD19-positive blood and lymph cancers

  This will test whether LV009 injections are safe for adults with relapsed or refractory CD19-positive non-Hodgkin lymphoma or acute lymphoblastic leukemia.

  Recruiting Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Suzhou, Jiangsu · NCT07284927

• PA3-17 (CD7-targeted CAR-T) injection for adults with CD7-positive relapsed/refractory T-lymphoblastic leukemia/lymphoma

  This will test a single infusion of PA3-17, a CD7-targeted CAR-T, in adults with CD7-positive relapsed or refractory T-lymphoblastic leukemia/lymphoma.

  Recruiting at 13 sites Phase 2 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Hefei, Anhui and 15 other locations · NCT07188610

• UTAA17 injection for treating relapsed or refractory multiple myeloma

  This study is testing a new injection called UTAA17 to see if it can safely help people with relapsed or refractory multiple myeloma.

  Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Suzhou, Jiangsu · NCT06279026

• TAA06 injection for treating B7-H3-positive neuroblastoma

  This study is testing a new T cell injection called TAA06 to see if it can safely help patients with hard-to-treat neuroblastoma that has come back.

  Recruiting Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Jinan, Shandong and 1 other locations · NCT05562024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.